Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kazia TherapeuticsKZIA -2.60%33 PS Ratio is 600.00 as of Sep. 09, 2026, which is 369% above its 10-year median of 127.95. GuruFocus rates KZIA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 936 Biotechnology companies, Kazia Therapeutics ranks worse than 94.55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kazia Therapeutics's share price is $12.00.
Kazia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02. Hence, Kazia Therapeutics's PS Ratio for today is 600.00.
The historical rank and industry rank for Kazia Therapeutics's PS Ratio or its related term are showing as below:
KZIA'
s PS Ratio Range Over the Past 10 Years
Min: 0.21 Med: 127.95 Max: 741.83
Current: 600
During the past 13 years, Kazia Therapeutics's highest PS Ratio was 741.83. The lowest was 0.21. And the median was 127.95.
KZIA's PS Ratio is ranked worse than 94.55% of 936
companies
in the Biotechnology industry
Industry Median: 9.52
vs KZIA: 600.00
During the past 13 years, Kazia Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 277.50% per year. The lowest was -61.10% per year. And the median was -16.55% per year.
Kazia Therapeutics (NAS:KZIA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Kazia Therapeutics PS Ratio Related Terms
Kazia Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Kazia Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kazia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kazia Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kazia Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kazia Therapeutics's Share Price of today is $12.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kazia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Kazia Therapeutics (KZIA) has a PS Ratio of 600.00 as of Sep. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kazia Therapeutics and its competitors. This is 369% above median its historical median of 127.95. Over the past decade, Kazia Therapeutics' PS Ratio has ranged from 0.21 to 741.83. According to the industry distribution chart, Kazia Therapeutics ranks #885 out of 936 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Kazia Therapeutics' PS Ratio too high?
Kazia Therapeutics' current PS Ratio of 600.00 is 369% above median its 10-year median of 127.95. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 741.83. The Biotechnology industry median PS Ratio is 9.52. Kazia Therapeutics' value of 600.00 is 6202.5% above this industry median. Based on the distribution chart, Kazia Therapeutics ranks #885 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kazia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kazia Therapeutics' PS Ratio compare to OKUR and TNYA?
According to the Biotechnology industry distribution chart, Kazia Therapeutics ranks #885 out of 936 companies for PS Ratio. This places Kazia Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.52. Kazia Therapeutics' value of 600.00 is 6202.5% above this benchmark. Historically, Kazia Therapeutics' own PS Ratio has ranged from 0.21 to 741.83 over the past decade. While the company's 10-year median is 127.95 vs. the industry median of 9.52, Kazia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kazia Therapeutics's current PS Ratio of 600.00 is 6202.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kazia Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kazia Therapeutics's current PS Ratio is 600.00, which is 369% above median its own 10-year median of 127.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kazia Therapeutics stock overvalued right now?
Kazia Therapeutics (KZIA) has a current PS Ratio of 600.00. The current PS Ratio is 600.00, which is 369% above median its 10-year median of 127.95 and 6202.5% above the Biotechnology industry median of 9.52. Kazia Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kazia Therapeutics (KZIA), the current PS Ratio is 600.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
33GF Score
Get the complete analysis for KZIA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KZIA has been successfully added to your 
